Eric Verdin, MD, is the president and CEO of the Buck Institute for Research on Aging; a professor at the Leonard Davis School of Gerontology at the University of Southern California; and a professor at the University of California, San Francisco.
Dr. Verdin discusses several breakthroughs, including:
How we can change our own personal rate of aging
Rapamycin as an example of a modulator of aging rate
Aging is the largest risk factor for non-communicable diseases
The need for healthcare to be reinvented as proactive care, not just sick care
The relative unimportance of our genetics to how well we age
I think Dr. Verdin is pointing the Buck Institute in the right direction, studying interventions that can be used soon or now to extend healthspan and lifespan. I donât agree with all of this diet advice, but thatâs par for the course. In general, he gives solid, mainstream advice while the Buck does more cutting edge research.
I missed that the first time. Thanks. Is he referring to ânumber needed to treatâ?
In my interview with Nathan Price (now of Thorne), he said variability in gut microbiome affected the effectiveness of statins. That said, donât cardiologists look at apoB or LDL to see if the statin is working?
Does anyone know what study (âwe knowâ) Verdin is referring to?
A very interesting YouTube video in case you missed it. This is the first time I have seen a company trying to commercialize an anti-aging strategy and provide it to everyone at the lowest possible cost. Their product is in phase 1&2 trials. Their main theory if I got it right is modulation of the immune system is the key to longevity. I hope their trial succeeds and they get their product to market as soon as possible at an affordable price.
In the meantime, we have rapamycin as an immune system modulator.
Thanks for finding this. This is great. Interesting that Peter Diamandis is connected to the company. Sounds like a really interesting product. Agreed, I hope the trial succeeds and they can get it to the masses quickly.
